Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. In a Phase 2 study in patients with myasthenia gravis, Descartes-08 was observed to be safe and well-tolerated, and to induce deep and durable responses. Cartesian plans to initiate a Phase 3 clinical trial of Descartes-08 in myasthenia gravis.
Minimum 15 minutes delayed. Source: LSEG
